Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | LIPA | P38571 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21518415 | 0.97 | EPHX1 (0.39) | EPHX1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL21518346 | 0.90 | EPHX1 (0.41) | EPHX1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL917789 | 0.86 | APP (0.39) | ALDH1A1KMT2ALMNAEPHX2S1PR4 | |
| SCHEMBL21518353 | 0.82 | APP (0.39) | ALDH1A1KMT2ALMNAEPHX2S1PR4 | |
| SCHEMBL4787562 | 0.82 | MEN1 (0.46) | EPHX1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL918632 | 0.81 | S1PR4 (0.36) | EPHX1ALDH1A1S1PR4S1PR1S1PR3 | |
| SCHEMBL918520 | 0.79 | CXCR4 (0.44) | ALDH1A1KMT2AS1PR4S1PR1S1PR3 | |
| SCHEMBL918238 | 0.79 | S1PR4 (0.41) | EPHX1MEN1ALDH1A1KMT2AS1PR4 | |
| SCHEMBL24429518 | 0.78 | MEN1 (0.41) | EPHX1MEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL11516269 | 0.78 | APP (0.38) | LMNAS1PR4S1PR1S1PR3GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107198-B1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-3560975-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-3724251-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3851472-B1 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-110396165-B | Ionically hydrophilicized polyisocyanates and antioxidants | 科思创德国股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112041369-B | Ionically hydrophilicized polyisocyanates, water content | 科思创知识产权两合公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115066445-A | Polyisocyanate formulations | 科思创德国股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-113651944-B | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11365277-B2 | Ionically hydrophilized polyisocyanates, water content | COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) | 2022-06-21 | — | — | US | disclosed |
| EP-3824009-B1 | IONICALLY HYDROPHILIZED POLYISOCYANATES WITH IMPROVED DRYING | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-01-31 | — | — | US | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| US-7253306-B2 | Pharmaceutical drug candidates and methods for preparation thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-08-07 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | EPHX1 812/4885MEN1 2282/4885ALDH1A1 2230/4885 |
| US-20080027097-A1 | PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF | MPST, TTR, STS | EPHX1 1371/4885MEN1 1137/4885ALDH1A1 78/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | EPHX1 574/4885MEN1 1011/4885ALDH1A1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.